Vnitr Lek 2007, 53(4):348-353

Molecular genetics of myocardial infarction

M. Aschermann1,*, K. Sedláček1, O. Aschermann2, A. Linhart1
1 II. interní klinika 1. lékařské fakulty a VFN Praha, přednosta prof. MUDr. Aleš Linhart, DrSc.
2 Kardiologické oddělení Nemocnice na Homolce, Praha, přednosta prof. MUDr. Petr Niederle, DrSc.

The incidence of atherosclerosis is very high and the typical risk factors such as lipids, blood pressure, smoking, dietary habits and lifestyle in general have an 80 % share in its development. Heredity also has a significant share and genome-related information has been given growing attention in recent years. A number of links between polymorphisms found at certain gene positions and the probability of acute myocardial infarction at a young age have been currently described. Cross-sectional studies have been focused on the identification of particular genotypes and alleles which can be responsible for early development of atherosclerosis and acute myocardial infarction. The article summarises some of the knowledge acquired so far in the field of genetic makeup of patients with acute myocardial infarction.

Keywords: genotype; molecular genetics; atherosclerosis; acute myocardial infarction

Received: April 4, 2007; Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Aschermann M, Sedláček K, Aschermann O, Linhart A. Molecular genetics of myocardial infarction. Vnitr Lek. 2007;53(4):348-353.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517. Go to original source... Go to PubMed...
    2. Piťha J, Hubáček A, Poledne R et al. Genetic determination og the prognosis in survivors of acute coronary syndromes. Study design and rationale for multicenter study. Cor Vasa 2007; 49: v tisku. Go to original source...
    3. Collins FS, Guyer MS, Charkravarti A Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278: 1580-1581. Go to original source... Go to PubMed...
    4. Databáze lidských monogenních onemocnění OMIM (Online Mendelian Inheritance in Man): http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
    5. Wilson PWF, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847. Go to original source... Go to PubMed...
    6. Conroy RM, Pyorala K, Fitzgerald AP et al. On behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
    7. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk of coronary heart disease. Ann Int Med 2004; 141: 137-147. Go to original source... Go to PubMed...
    8. Casserly IP, Topol EJ. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and unfolded proteins. Lancet 2004; 263: 1139-1146. Go to original source... Go to PubMed...
    9. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000; 101: 1366-1371. Go to original source... Go to PubMed...
    10. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group. N Engl J Med 1998; 338: 86-93. Go to original source... Go to PubMed...
    11. Yamada Y, Izawa H, Ichihara S et al. Prediction of risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-1923. Go to original source... Go to PubMed...
    12. Topol EJ, McCarthy J, Gabriel S et al (for the GeneQuest investigators and collaborators). Single nucleotide polymorphisms in multiple novel thrombospondine genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-2644. Go to original source... Go to PubMed...
    13. Tobin MD, Braund PS, Burton PR et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 2004; 25: 459-467. Go to original source... Go to PubMed...
    14. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654. Go to original source... Go to PubMed...
    15. Ozaki K, Inoue K, Sato H et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 2004; 429: 72-75. Go to original source... Go to PubMed...
    16. Glazier AM, Naderu JH, Altman TJ. Finding genes that underlie complex traits. Science 2003; 298: 2345-2349. Go to original source... Go to PubMed...
    17. Topol EJ. The genomic basis of myocardial infarction. J Am Coll Cardiol 2005; 46: 1456-1465. Go to original source... Go to PubMed...
    18. Wang Q, Rao S, Shen GQ et al. Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genome-wide linkage analysis. Am J Hum Genet 2004; 74: 262-271. Go to original source... Go to PubMed...
    19. Wang L, Fan C, Topol SE et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003; 302: 1578-1581. Go to original source... Go to PubMed...
    20. Wang L, Kavaslar N, Ustaszewska A et al. Lack of MEF2A mutation s in coronary artery disease. J Clin Incest 2005; 115: 1016-1020. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.